ID   MCF10A PTEN-/- KRas(G12V) clone 1
AC   CVCL_F6KS
SY   PTEN-/-KRAS(G12V) clone 1
RX   PubMed=26497685;
CC   Characteristics: Tumorigenic in nude-Foxn1nu mice (PubMed=26497685).
CC   Knockout cell: Method=Homologous recombination; HGNC; HGNC:9588; PTEN.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:6407; KRAS (Note=With p.Gly12Val).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P00552; Klebsiella pneumoniae transposon Tn5 neo.
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008367.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_F6LY ! MCF-10A PTEN(-/-)
SX   Female
AG   36Y
CA   Spontaneously immortalized cell line
DT   Created: 22-10-26; Last updated: 22-10-26; Version: 1
CH   CVCL_F6KW ! PTEN-/-KRAS(G12V)-Luc
//
RX   PubMed=26497685; DOI=10.18632/oncotarget.6159; PMCID=PMC4742101;
RA   Thompson, Keyata N.
RA   Whipple, Rebecca A.
RA   Yoon, Jennifer R.
RA   Lipsky, Michael
RA   Charpentier, Monica S.
RA   Boggs, Amanda E.
RA   Chakrabarti, Kristi R.
RA   Bhandary, Lekhana
RA   Hessler, Lindsay K.
RA   Martin, Stuart S.
RA   Vitolo, Michele I.
RT   "The combinatorial activation of the PI3K and Ras/MAPK pathways is
RT   sufficient for aggressive tumor formation, while individual pathway
RT   activation supports cell persistence.";
RL   Oncotarget 6:35231-35246(2015).
//